Comment on Kridin et al.-Considering both relative and absolute risk differences in infection risk between biologics classes in patients with psoriasis

J Eur Acad Dermatol Venereol. 2024 Apr;38(4):e351-e353. doi: 10.1111/jdv.19615. Epub 2023 Nov 12.

Authors

James P Pham^{1

2

3}, Rebecca Jepsen^{1

2}, John W Frew^{1

2

3}

Affiliations

¹ Department of Dermatology, Liverpool Hospital, Liverpool, New South Wales, Australia.
² Laboratory of Translational Cutaneous Medicine, Ingham Institute for Applied Medical Research, Liverpool, New South Wales, Australia.
³ School of Clinical Medicine, UNSW Medicine and Health, Sydney, New South Wales, Australia.

PMID: 37908185
DOI: 10.1111/jdv.19615

No abstract available

Publication types

Letter

MeSH terms

Biological Factors
Biological Products* / adverse effects
Disease Susceptibility
Etanercept
Humans
Psoriasis* / drug therapy

Substances

Biological Products
Biological Factors
Etanercept